Geron logo

GeronNASDAQ: GERN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 July 1996

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.24 B
-26%vs. 3y high
82%vs. sector
-vs. 3y high
-vs. sector
-59%vs. 3y high
89%vs. sector
-99%vs. 3y high
94%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:45:08 GMT
$3.70-$0.04(-1.07%)

Dividend

No data over the past 3 years
$28.27 M$62.16 M
$28.27 M-$26.45 M

Analysts recommendations

Institutional Ownership

GERN Latest News

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
businesswire.com11 November 2024 Sentiment: POSITIVE

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development, effective today, November 11, 2024. In this role, Dr. Eid will lead our Research and Development organization comprised of medical, clinical, and safety/pharmacovigilance teams and be responsible for driving inno.

Geron: A Post Earnings And Funding Announcement Assessment
seekingalpha.com07 November 2024 Sentiment: POSITIVE

Geron Corporation's imetelstat, now branded as Rytelo, was finally approved by the FDA in June for treating lower risk myelodysplastic syndromes and has shown solid initial sales traction. The company just reported third quarter results and announced a new financing arrangement. Analyst firms are positive on the company's prospects. An updated analysis of Geron Corporation follows in the paragraphs below.

Geron Corporation (GERN) Q3 2024 Earnings Call Transcript
seekingalpha.com07 November 2024 Sentiment: NEUTRAL

Geron Corporation (NASDAQ:GERN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Aron Feingold - Vice President of IR and Corporate Communication John Scarlett - Chairman and CEO Jim Ziegler - EVP and CCO Michelle Robertson - EVP and CFO Faye Feller - EVP, CMO Andrew Grethlein - EVP, COO Conference Call Participants Tara Bancroft - T. D. Cowen Faisal Khurshid - Leerink Partners Corinne Johnson - Goldman Sachs Carter Gould - Barclays Emily Bodnar - H.C.

Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
zacks.com07 November 2024 Sentiment: POSITIVE

Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
businesswire.com07 November 2024 Sentiment: POSITIVE

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up to $375 million in synthetic royalty and debt financings with Royalty Pharma and investment funds managed by Pharmakon Advisors, LP, of which $250 million in cash was provided at closing and another $125 million in debt is available. The transactions are comprised of a $125 million synthetic royalty.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com17 October 2024 Sentiment: POSITIVE

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 680,220 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16, 2024, at an exercise price of $4.17 per share, which is equal to the closing price of Geron common stoc.

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
businesswire.com15 October 2024 Sentiment: POSITIVE

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and business highlights before the market opens on Thursday, November 7, 2024 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. ET the same day. A.

Geron: Derisked And Highly Attractive After Approval
seekingalpha.com23 September 2024 Sentiment: POSITIVE

Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise in treating MDS and MF, with significant clinical trial results and manageable adverse events. Geron's financials are strong with a $2.8bn market cap and cash runway until 2026, positioning it well for future growth.

Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS
businesswire.com26 July 2024 Sentiment: POSITIVE

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of Myelodysplastic Syndromes (MDS) to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk MDS.

  • 1(current)
  • 2
  • 3

What type of business is Geron?

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

What sector is Geron in?

Geron is in the Healthcare sector

What industry is Geron in?

Geron is in the Biotechnology industry

What country is Geron from?

Geron is headquartered in United States

When did Geron go public?

Geron initial public offering (IPO) was on 31 July 1996

What is Geron website?

https://www.geron.com

Is Geron in the S&P 500?

No, Geron is not included in the S&P 500 index

Is Geron in the NASDAQ 100?

No, Geron is not included in the NASDAQ 100 index

Is Geron in the Dow Jones?

No, Geron is not included in the Dow Jones index

When was Geron the previous earnings report?

No data

When does Geron earnings report?

The next expected earnings date for Geron is 28 February 2025